BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12592335)

  • 1. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
    Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
    Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
    Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
    Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
    Gozzini A; Santini V
    Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
    Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
    Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
    Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
    J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
    Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
    Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    Wang J; Saunthararajah Y; Redner RL; Liu JM
    Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO.
    Duque-Afonso J; Yalcin A; Berg T; Abdelkarim M; Heidenreich O; Lübbert M
    Oncogene; 2011 Jul; 30(27):3062-72. PubMed ID: 21577204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
    Fliegauf M; Stock M; Berg T; Lübbert M
    Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
    Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
    Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
    Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
    Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
    J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
    Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
    FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
    Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V
    Epigenetics; 2014 Mar; 9(3):387-95. PubMed ID: 24300456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
    Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
    Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
    Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
    Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.